Claims for Patent: 5,312,628

Summary for Patent: 5,312,628

Title:	Isolation of a soluble 42 KD pancreatic islet cell autoantigen
Abstract:	A method of isolating soluble pancreatic islet antigen employs extraction with a non-ionic detergent and fractionation on a gel filtration column. Fractions are screened for high immunoreactivity with diabetic serum which is positive for ICA immunofluorescence when tested on tissue sections of a pancreas from a human blood group O donor. The isolated soluble antigen is suitable for measuring autoantibodies in both complement fixation assays as well as ELISA-type and immunoblotting formats. Methods of using isolated soluble antigen to test serum for autoantibodies are also taught.
Inventor(s):	Cohen; Margo P. (New York, NY), Wu; Van-Yu (Cherry Hill, NJ)
Assignee:	Exocell, Inc. (Philadelphia, PA)
Application Number:	08/059,719
Patent Claims:	1. A cell-free antigenic preparation useful for measuring autoantibody titers in blood, said preparation comprising a detergent-soluble antigen which immunologically binds to circulating autoantibodies to pancreatic islet cells associated with diabetes mellitus, wherein said preparation immunologically binds at least two-fold less to antibodies in serum from non-diabetic humans than to antibodies in serum from diabetic humans, wherein said antigen has a molecular weight of between 40 and 45 kD when measured on SDS-polyacrylamide gels, wherein said antigen is obtainable from pancreases of humans having an HLA type selected from the group consisting of HLA-DR 7; HLA-DR 1, w-11; HLA-DR 11,7; and HLA-DR 2,4, and wherein said antigen is substantially purified from other antigens which are not immunologically reactive with diabetes-specific, islet cell antibodies. 2. The preparation of claim 1 wherein said antigen immunologically binds to said circulating autoantibodies in the denatured state. 3. The preparation of claim 1 wherein the soluble islet cell antigen is not radiolabeled. 4. The preparation of claim 1 wherein the soluble islet cell antigen is not reduced. 5. The preparation of claim 1 which is devoid of sodium dodecylsulfate. 6. A cell-free antigenic preparation useful for measuring autoantibody titers in blood, said preparation comprising a detergent-soluble antigen which immunologically binds to circulating autoantibodies to pancreatic islet cells associated with diabetes mellitus, wherein said preparation immunologically binds at least two-fold less to antibodies in serum from non-diabetic humans than to antibodies in serum from diabetic humans, said antigen being substantially purified from other antigens which are not immunologically reactive with diabetes-specific, islet cell antibodies, said antigen having a molecular weight of between 40 and 45 Kd when measured on SDS-polyacrylamide gels, said antigen being obtainable from pancreases of humans having an HLA type selected from the group consisting of HLA-DR 7; HLA-DR 1, w-11; HLA-DR 11,7; and HLA-DR 2,4, said antigenic preparation made by the process of: lysing and extracting islet cells from human pancreas to provide a cell-free extract containing soluble islet cell autoantigen; fractionating components of the cell-free extract to provide fractionated soluble components; testing the fractionated soluble components in denatured state for immunological binding to circulating autoantibodies to pancreatic islet cells associated with diabetes mellitus; selecting the fractionated soluble components with maximum immunological binding in the denatured state. 7. The preparation of claim 6 wherein: immunoglobulin molecules are removed from the lysed and extracted cells. 8. The preparation of claim 7 wherein immunoglobulin molecules are removed from the lysed and extracted islet cells using a protein-A column on HPLC. 9. The preparation of claim 6 wherein: the step of fractionating is on the basis of size. 10. The preparation of claim 9 wherein: the step of fractionating is on a Waters SW-300 gel filtration column on HPLC. 11. The preparation of claim 6 wherein: the step of fractionating employs an ion exchange resin. 12. The preparation of claim 11 wherein: the ion exchange resin is DEAE-5pw. 13. The preparation of claim 6 wherein: the step of fractionating employs SDS-polyacrylamide gel electrophoresis. 14. The preparation of claim 6 wherein the step of lysing is done by freezing and thawing the islet cells. 15. The preparation of claim 6 wherein the step of extracting employs Triton X-100.TM. (polyoxyethylene glycol tert-octlyphenyl ether). 16. The preparation of claim 6 wherein islet cells are isolated from pancreatic tissue after collagenase digestion. 17. A method for isolating a detergent soluble autoantigen which is capable of immunologically binding to circulating autoantibodies to pancreatic islet cells associated with diabetes mellitus, wherein said autoantigen immunologically binds at least two-fold less to antibodies in serum from non-diabetic humans than to antibodies in serum from diabetic humans, said autoantigen being substantially purified from other antigens which are not immunologically reactive with diabetes-specific islet cell antibodies, said autoantigen having a molecular weight of between 40 and 45 kD when measured on SDS-polyacrylamide gels, said antigen being obtainable from pancreases of humans having an HLA type selected from the group consisting of HLA-DR 7; HLA-DR 1, w-11; HLA-DR 11,7; and HLA-DR 2,4, said method comprising: lysing and extracting islet cells from human pancreas to provide a cell-free extract containing said soluble islet cell autoantigen; fractionating components of the cell-free extract to provide fractionated soluble components; testing the fractionated soluble components in the denatured state for immunological binding to circulating autoantibodies to pancreatic islet cells associated with diabetes mellitus; selecting the fractionated soluble components with maximum immunological binding in the denatured state. 18. The method of claim 17 wherein: immunoglobulin molecules are removed from the lysed and extracted islet cells. 19. The method of claim 18 wherein immunoglobulin molecules are removed from the lysed and extracted islet cells using a protein-A column on HPLC. 20. The method of claim 17 wherein: the fractionation is on the basis of size. 21. The method of claim 20 wherein: fractionation is on a Waters SW-300 gel filtration column on HPLC. 22. The method of claim 17 wherein: the fractionation employs an ion exchange resin. 23. The preparation of claim 22 wherein: the ion exchange resin is DEAE-5pw. 24. The method of claim 17 wherein: the fractionation employs SDS-polyacrylamide gel electrophoresis. 25. The method of claim 17 wherein the step of lysing is done by freezing and thawing the islet cells. 26. The method of claim 17 wherein the step of extracting employs Triton X-100.TM. (polyoxyethylene glycol tert-octylphenyl ether). 27. The method of claim 17 wherein islet cells are isolated from pancreatic tissue after collagenase digestion.

Details for Patent 5,312,628

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2011-05-17